Radiation therapy for early stage unfavorable Hodgkin lymphoma: is dose reduction feasible?

References

• Gisselbrecht C, Mounier N, Andre M, et al. How to define intermediate stage in Hodgkin's lymphoma? Eur J Haematol Suppl 2005;(86):11–14.
   Google Scholar
• Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006;24:3128–3135.
   PubMed Web of Science ®Google Scholar
• Fermé C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved field radiation in early stage Hodgkin's disease. N Engl J Med 2007;357:1916–1927.
   PubMed Web of Science ®Google Scholar
• Cosset JM, Henry-Amar M, Meerwaldt JH. Long term toxicity of early stages of Hodgkin‘s disease therapy: the EORTC experience. Ann Oncol 1991;2(Suppl. 2):77–82.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Adhikari A, Rizk N, et al. Effect of treatment for Hodgkin's disease on pulmonary function: results of a prospective study. J Clin Oncol 1994;12:297–305.
   PubMed Web of Science ®Google Scholar
• Loeffler M, Brosteau O, Hasenclever D, et al. Meta-analysis of chemotherapy vs. combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Study Group. J Clin Oncol 1998;16:818–829.
   PubMed Web of Science ®Google Scholar
• Ferme C, Eghbali H, Hagenbeek A, et al. MOPP/ABV hybrid and irradiation in unfavourable supra-diaphragmatic clinical stages I–II Hodgkin's disease: comparison of three treatment modalities. Preliminary results of the EORTC-GELA H8-U randomized trial in 995 patients. Blood 2000;96(Suppl. 1): Abstract 576.
   Google Scholar
• Ferme C, Divine M, Vranovsky A, et al. Four ABVD and involved-field radiotherapy in unfavourable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): preliminary results of the EORTC-GELA H9-U trial. Blood 2005;106(Suppl. 1): Abstract 813.
   Google Scholar
• Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 Trial. J Clin Oncol 2010;28:4199–4206.
   PubMed Web of Science ®Google Scholar
• von Tresckow B, Plutschow A, Fuchs M, et al. Dose- intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVDand involved field radiotherapy (IFRT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin lymphoma (HL): an analysis of the German Hodgkin Study Group (GHSG) HD14 trial. J Clin Oncol 2012;30: 907–913.
   PubMed Web of Science ®Google Scholar
• Advani R, Hoppe T, Lauren S, et al. Stage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience. Int J Radiat Oncol Biol Phys 2011;81:1374–1379.
   PubMed Web of Science ®Google Scholar
• Ng AK, Bernardo MVP, Weller E, et al. Second malignancy after Hodgkin's disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002;100: 1989–1996.
   PubMed Web of Science ®Google Scholar
• Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 2014;89:854–862.
   PubMed Web of Science ®Google Scholar
• Levi JA, Wiernik PH. Limited extranodal Hodgkin's disease. Unfavorable prognosis and therapeutic implications. Am J Med 1977;63:365–372.
   PubMed Web of Science ®Google Scholar
• Leslie NT, Mauch PM, Hellman S. Stage IA to IIB supradiaphragmatic Hodgkin's disease. Long-term survival and relapse frequency. Cancer 1985;55:2072–2078.
   PubMed Web of Science ®Google Scholar
• Connors JM, Klimo P. Is it an E lesion or stage IV? An unsettled issue in Hodgkin's disease staging. J Clin Oncol 1984;2:1421–1423.
   PubMed Web of Science ®Google Scholar
• Nogova L, Reineke T, Brillant C, et al. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008;26:434–439.
   PubMed Web of Science ®Google Scholar
• Carde P, Koscielny S, Franklin J, et al. Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity? Ann Oncol 2002;13(Suppl. 1):86–91.
   PubMed Web of Science ®Google Scholar
• Gobbi PG, Broglia C, Di Giulio G, et al. The clinical value of tumor burden at diagnosis in Hodgkin lymphoma. Cancer 2004; 101:1824–1834.
   PubMed Web of Science ®Google Scholar
• Tubiana M, Henry-Amar M, Van Der Werf-Messing, et al. A multivariate analysis of prognostic factors in early Hodgkin's disease. Int J Radiat Oncol Biol Phys 1985;11:23–30.
   PubMed Web of Science ®Google Scholar
• Henry-Amar M, Somers R. Survival outcome after Hodgkin's disease: a report from the International Data Base on Hodgkin's Disease. Semin Oncol 1990;17:758–768.
   PubMed Web of Science ®Google Scholar